With extensive interdisciplinary entrepreneurial experience and corporate
management capabilities, Sizhen Wang leads Genetron Health in exploring cancer genomics and
promoting bio-innovative technology applications to further the development of human
Co-founder & Chief Executive Officer
In 2013 co-founded Genetron Health, a leading precision oncology platform company in China.
Genetron Health’s service portfolio covers the full-cycle of cancer care from early screening,
diagnosis and treatment recommendations, to continuous monitoring and continuous care. The
company has since served tens of thousands of cancer patients, high-risk groups, hundreds of
hospitals and medical examination centers, dozens of pharmaceutical firms and research
institutes as well as public health programs around the world. In June 2020, the company listed
on Nasdaq under the ticker GTH in one of the largest ever precision oncology medicine company
IPOs to date.
In 2004 co-founded iTalkBB, a company providing global telephone, TV, data and mobile
communication services to millions of users around the world. iTalkBB is now the leading
Internet communication brand among Chinese communities in North America and Australia.
Seven years in the finance industry at Capital One and GD Capital
Seven years in the finance industry at Capital One and GD Capital
MBA, HEC Paris School of Management
Mr. Hong has over 20 years of experience in market operation and management in
the medical treatment and health field.
Chief Operating Officer
General Manager of China and Vice President of North Asia for C. R. Bard Inc.; responsible
for founding and leading Bard’s functions in North Asia
Marketing Director of Johnson & Johnson Medical China and Director of the Surgery Department
of Johnson & Johnson Medical China; responsible for department’s P&L and management
MBA, William E. Simon Graduate School of Business Administration, University of
Spent more than 12 years in international investment banks, with extensive
experience in corporate finance and M&A. Previously held the sponsor principal license granted by
Securities and Futures Commission, Hong Kong.
Chief Financial Officer
Helped Genetron Health successfully listed in Nasdaq, as the largest IPO of precision
oncology globally by then
Director of the Investment Banking Division at Deutsche Bank AG, Hong Kong in
Executive Director of the Investment Banking Division of Goldman Sachs (Asia) L.L.C in 2010
Manager of Lehman Brothers (Hong Kong) and Nomura Securities in 2008-2010
Management Trainee of Citigroup in 2006-2008
Master’s degree from the National University of Singapore
Victoria is a visionary global
business leader with extensive management experience in a diversity of industries across North
America and Asia. Her expertise has been well-demonstrated in the areas of experiential marketing
with design thinking, business development and branding. Being a seasoned entrepreneur and a
Fortune 500 corporate manager at different heights during her career, Victoria’s multi-faceted
experience saw her leading many successful new product launches from conceptualization to
delivery. She is especially accomplished in developing integrated branding and go-to-market growth
strategies for high-tech products with deep knowledge in consumer insights.
Senior Vice President
18 years of experience in hospitality management, internet and life sciences
Victoria holds a bachelor’s degree in hotel management from the University of South Carolina
and Hotel Institute Montreux, Switzerland.
GMP from Harvard Business School.
With over 30 years of management
experience at Fortune 500 companies, Cathy brings valuable knowledge and competence in overseas
market expansion and team management to Genetron Health. She has led the Alcatel-Lucent’s overseas
business operations. As part of Genetron Health’s senior management team, Cathy has spearheaded
and participated in the successful wins of several major national and local government projects.
She is also in charge of intellectual property rights and market entry strategies.
Previously worked for HP China and Ericsson.
Held key positions of sales and government affairs director as well as vice president of
overseas markets at Alcatel.
Shanghai Fudan University School of Management, University of Hong Kong MBA
A well-rounded HR practitioner with extensive experience in banking, FMCG,
logistics and consulting industries. She has demonstrated deep understanding and strong capability
in organizational design, performance management, talent development, staff engagement, change
management and HR transformation functions. She is also well-versed in talent pipeline, succession
planning as well as corporate culture development.
Over 20 years of experience in Human Resources. Prior to joining Genetron Health, she helmed
the Human Resources Department at Standard Chartered Bank. During her eight years with the bank,
she has worked closely with the country CEO and branch managers in rolling out HR initiatives
across all 28 branches in China.
Bachelor’s and master’s degree in biology, Peking University.
With over a decade of experience in the pharmaceutical industry, Lin Teng has
strong interest and is passionately involved in cancer care research work. She has a proven track
record of success in marketing and team management at top pharmaceutical companies focusing on
7 years of experience in biomedical services sector, including with Roche and
Bachelor of Medicine, Shandong University.
Yin has over 25 years of experience in commerce, sales and management in health
care, all of which rank among the top 10 pharmaceutical enterprises globally. He has extensive
experience in the fields of IVD, gene sequencing and related equipment or high-value supplements,
particularly in building a comprehensive dealer system from scratch, with successful experience in
graded sales management.
Yin previously served as deputy general manager of Guangzhou Darui Biotechnology Co. Ltd,
founded the overseas testing company Ruikang International and served as general manager,
established the operating team and doubled the revenue.
Previously served as the business and sales director at Becton, Dickinson and Company, as
well as Abbott
Yin has held sales and management positions at Johnson & Johnson and GSK
He is a licensed anesthesiologist
He graduated from Southeast University with a major in clinical medicine, and was a visiting
scholar at Stanford University School of Medicine
Hai Yan is Henry S. Friedman Endowed Chair of Neuro-Oncology, and Professor of
Pathology at Duke University. He is a member of American Society for Clinician Investigation
Co-founder & Chief Scientific Officer
Received his PhD from Columbia University and post-doctoral training at The Johns Hopkins.
Best known for his discovering isocitrate dehydrogenase (IDH1, IDH2) and TERT promoter
mutations in gliomas. Molecular criteria for gliomas based on his pioneering work are now placed
in the World Health Organization IARC Blue Book Classification of CNS Tumors.
Published more than 120 SCI papers, including articles in NEJM, Science, Nature, PNAS， and
CNS subsidiary journals, either as a first or corresponding author.
The inventor of BEAMing technology, a core technology for cfDNA detection, which has been
clinically implemented in liquid biopsy.
M.D. from Peking Union Medical College Ph.D. from the Johns Hopkins
University School of Medicine
Dr. Yuchen Jiao
Chief Technology Officer
Studied the cancer genomics of various tumors, and identified novel tumor suppressor genes
including ATRX, which were listed as an important diagnostic marker by the WHO classification of
tumours of the central nervous system.
Published more than 20 research papers in Science, Nature Genetics, PNAS and other journals
as first or corresponding author
Postdoctoral training in the team of Professor Bert Vogelstein
Dr. Hu has more than two decades of experience in regulatory and business
management related to medical devices and pharmaceutical R&D industries.
Dr. Yunfu Hu
Chief Medical Officer
Under Dr. Hu’s leadership, Genetron Health’s blood-based next-generation sequencing (NGS)
test, HCCscreenTM, received Breakthrough Device designation from the U.S. Food and Drug
Administration (FDA), which made it the first product in China's molecular diagnostic industry
to achieve this recognition.
Dr. Hu previously served as Deputy Director of the Division of Molecular Genetics and
Pathology in the Office of In Vitro Diagnostics and Radiological Health, Center for Devices and
Radiological Health at FDA. He was responsible for supervising in vitro diagnostic products such
as cancer molecular diagnosis, companion diagnostic products, gene testing, artificial
intelligence in pathology and cytological detection.
Some of his notable FDA approvals include: Myriad Genetics' BRACAnalysis CDx ; Foundation
Medicine FoundationFocus CDxBRCA; ThermoFisher Oncomine Dx Target Test; FoundationOne CDx; Roche
Cobas EGFR Mutation Test v2; Exact Sciences’ Cologuard and Epigenomics’ Epi ProColon.
Dr. Hu has 10 years of product development experience with world-class diagnostic and
pharmaceutical companies. He has made outstanding achievements in precision medical research,
tumor biomarker development and diagnostic product development and registration.
Ph.D., veterinary physiology & pharmacology and M.S., reproductive endocrinology at Ohio
State University; Postdoctoral Fellow of Fox Chase Cancer Center.